Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2014 · 10-K
Revenue$127.28M$127.28M+492.5% vs Q4 2013 Net Income$86.75M$86.75MderivedN/M vs Q4 2013 EPS Diluted$0.76$0.76N/M vs Q4 2013 Operating Income$88,360,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived$265,924,000N/M Free Cash Flowderived$265,678,000N/M Margins · derivedOperating margin69.4%+85.5 pt vs Q4 2013
Net margin68.2%+81.8 pt vs Q4 2013
ended Dec 31, 2015 · filed Mar 11, 2016 · 71 d after period end